Table 3 Baseline model parameters (based on [2, 4])
| Parameter | Hydrocele average estimate | Lymphedema average estimate | Source |
|---|---|---|---|
| Acute Disease | |||
| Percentage of clinical patients who experience ADL episodes per year | 70 % | 95 % | [8, 10–17] |
| Frequency of ADL episodes for clinical patients (in absence of MDA) | 2 per year | 4 per year | [8, 10–17] |
| Average duration of an ADL episode | 4 days | 4 days | [8, 10–17] |
| Reduction in the frequency of ADL episodes by MDA | 50 % | 50 % | [33, 36, 37] |
| Chronic Disease | |||
| Percentage in different clinical disease states | 62.5 % | 37.5 % | [7] |
| Percentage of chronic disease alleviated by MDA | 10 % | 15 % | [20, 30–35] |